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Abstract Heart failure represents a common disease
affecting approximately 5 million patients in the United
States. Several conditions play an important role in the
development and progression of heart failure, including
abnormalities in myocardial blood ﬂow and sympathetic
innervation. Nuclear imaging represents the only imaging
modality with sufﬁcient sensitivity to assess myocardial
blood ﬂow and sympathetic innervation of the failing heart.
Although nuclear imaging with single-photon emission
computed tomography (SPECT) is most commonly used
for the evaluation of myocardial perfusion, positron emis-
sion tomography (PET) allows absolute quantiﬁcation of
myocardial blood ﬂow beyond the assessment of relative
myocardial perfusion. Both techniques can be used for
evaluation of diagnosis, treatment options, and prognosis in
heart failure patients. Besides myocardial blood ﬂow, car-
diac sympathetic innervation represents another important
parameter in patients with heart failure. Currently, sym-
pathetic nerve imaging with 123-iodine metaiodobenzyl-
guanidine (123-I MIBG) is often used for the assessment of
cardiac innervation. A large number of studies have shown
that an abnormal myocardial sympathetic innervation, as
assessed with 123-I MIBG imaging, is associated with
increased mortality and morbidity rates in patients with
heart failure. Also, cardiac 123-I MIBG imaging can be
used to risk stratify patients for ventricular arrhythmias or
sudden cardiac death. Furthermore, novel nuclear imaging
techniques are being developed that may provide more
detailed information for the detection of heart failure in an
early phase as well as for monitoring the effects of new
therapeutic interventions in patients with heart failure.
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Heart failure
The clinical syndrome of heart failure remains an important
condition with markedly increased morbidity and mortality
rates over the last several decades [1, 2]. The American
Heart Association Statistics and Stroke Statistics Com-
mittee have reported that the estimated life-time risk for
development of heart failure is approximately 20% at the
age of 40 years [2]. At present, a total number of 5,300,000
patients have been diagnosed with heart failure in the
United States, representing about 2.5% of the population
aged C20 years. Moreover, heart failure represents a con-
siderable health care issue as the number of annual hospital
admissions grew dramatically by 171%, from 400,000 in
1979 to 1,084,000 in 2005 [2]. Beyond the increasing
number of newly diagnosed heart failure patients and
hospital admissions, heart failure accounts for a large
number of cardiac deaths in the western world, with an
estimated 5-year mortality rate of 54% in men and 40% in
women [3].
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DOI 10.1007/s10741-010-9196-0Heart failure is considered a complex clinical syndrome
resulting from a decreased cardiac pump capacity which
lacks the ability to provide sufﬁcient metabolic demands to
peripheral tissues. The progressive loss of functional and
viable cardiomyocytes and the inability of viable myocar-
dium to contract normally play an important role in
development of heart failure. In patients with heart failure,
several underlying mechanisms have been identiﬁed that
interact markedly in the pathophysiology of dysfunctional
myocardium, including abnormalities in coronary ﬂow,
myocardial blood ﬂow, cell metabolism, and sympathetic
innervation of the myocardium.
Regardless of the underlying pathophysiologic mecha-
nisms, various compensatory feedback systems, including
the sympathetic nervous system and renin–angiotensin–
aldosterone system, are activated in patients with heart
failure which aim to modulate the deprived cardiac pump
functionwithin a normal homeostaticrange [4–7].Although
activated feedback systems act favorably in the early phase
bypositiveinotropic,chronotropic,anddromotropiceffects,
they become deleterious ina chronicstate as they may cause
myocardial hypertrophy and ﬁbrosis, leading to cardiac
remodeling and restructuring. Accordingly, secondary end-
organ damage of the myocardium may further enhance the
progressive decline in cardiac function, resulting in overt
clinical symptoms of heart failure.
A comprehensive evaluation of heart failure patients
remains challenging these days, as it requires integrated
information on heart failure etiology, pathophysiology and
prognosis. At present, heart failure patients can be evalu-
ated with the use of different non-invasive imaging tech-
niques, including echocardiography, magnetic resonance
imaging as well as nuclear imaging. Among the currently
available imaging techniques, nuclear imaging represents
the only imaging modality with sufﬁcient sensitivity to
provide insights into myocardial and cellular mechanisms
involved in the etiology, pathophysiology and prognosis of
patients with heart failure [8, 9]. More speciﬁcally, nuclear
imaging provides detailed information on several biologi-
cal processes in heart failure, including myocardial blood
ﬂow and sympathetic innervation of the myocardium,
which are considered important tissue characteristics of the
failing heart.
Accordingly, the current review will provide an over-
view of the potential role of nuclear imaging techniques for
tissue characterization in patients with heart failure, with
particular focus on the assessment of myocardial blood
ﬂow and sympathetic innervation of the failing heart. In
addition, the potential role of molecular imaging in the
ﬁeld of heart failure will be provided; novel techniques
may help in prevention of development of heart failure and
could possibly guide novel therapeutic options for heart
failure.
The potential of nuclear imaging in heart failure
Myocardial perfusion imaging represents the mainstay of
cardiovascular radionuclide applications for the diagnostic
and prognostic workup of patients with coronary artery
disease and heart failure [10]. In addition, sympathetic
innervation imaging is increasingly used in patients with
heart failure, predominantly for risk stratiﬁcation.
At the same time, considerable improvements in nuclear
imaging technology have led to an evolution of clinical
nuclear imaging beyond the isolated assessment of myo-
cardial perfusion and sympathetic innervation, toward the
characterization of molecular processes at the cardiac tis-
sue level.
Several technical advances have been introduced that
contribute to the current trend toward molecular-targeted
imaging in clinical cardiology. At ﬁrst, the availability of
high-end scanner systems with improved detection sensi-
tivity and image resolution allow the detection of weak
signals coming from tissue-speciﬁc molecular-targeted
tracers. Furthermore, the availability of positron emission
tomography (PET) systems has increased markedly over
the recent years due to its success in oncology [9]. More-
over, an increasing number of molecular-targeted radio-
tracers is now being introduced which may extend the
current possibilities for molecular imaging of biologic
processes. Finally, it is important to note that molecular-
targeted imaging is of growing interest as nuclear systems
are increasingly integrated with computed tomography
(CT) systems into single-photon emission computed
tomography (SPECT)-CT or PET-CT hybrid imaging
devices, which facilitate the localization of a molecular
signal, by fusion with high-resolution morphologic
images [9].
Potentially, these dedicated nuclear imaging techniques
with their unique translational potential and their superior
detection sensitivity can play an important role in the
evaluation of patients with heart failure as they provide
important information on several biological processes of
the failing heart, including myocardial blood ﬂow and
sympathetic innervation of the myocardium.
Myocardial blood ﬂow in the failing heart
Myocardial perfusion can be evaluated with the use of
different nuclear imaging techniques, including SPECT
and PET imaging. Myocardial perfusion SPECT represents
a well-established and safe imaging modality for the evalu-
ation of location, extent and severity of myocardial per-
fusion defects [11]. In clinical cardiology, 3 commercially
available SPECT tracers (
201Thallium,
99mTc-tetrofosmin,
and
99mTc-sestamibi) (Table 1) are most commonly used to
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123evaluate the presence, extent, and reversibility of myo-
cardial perfusion defects in patients with suspected or
known coronary artery disease.
Although myocardial perfusion SPECT is still the clin-
ical mainstay, PET imaging is being increasingly utilized
in clinical cardiovascular imaging practice [9]. It has been
shown that PET imaging allows accurate detection of sig-
niﬁcant coronary artery disease, which may be superior to
SPECT imaging in particular subsets of patients [12].
Moreover, it is important to note that PET imaging pro-
vides information beyond the assessment of relative
regional myocardial perfusion. In PET imaging, high
temporal resolution and additional methodological advan-
tages enable the absolute quantiﬁcation of myocardial
blood ﬂow and ﬂow reserve, contributing to the assessment
of underlying etiology of heart failure (ischemic versus
non-ischemic cardiomyopathy). Hypoperfusion of the
myocardium, either due to macro-vascular ﬂow-limiting
coronary artery disease or abnormalities in coronary
microcirculatory ﬂow, will lead to distortion of fatty acid
and glucose cell metabolism as well as the myocardial
storage of high-energy and creatine phosphates, and as a
consequence, can cause a dysfunctional contraction pattern
of the myocardium. Furthermore, chronic myocardial
hypoperfusion may result in irreversible loss of functional
and cellular integrity, leading to cell death and ﬁbrosis [5].
Several PET tracers are currently available for assess-
ment of myocardial perfusion (Table 1), of which N-13
Ammonia (
13NH3) and Rubidium-82 (
82Rb) are both
approved for clinical use by the US Food and Drug
Administration (FDA). Both
13NH3 and
82Rb can be used
for absolute quantiﬁcation of myocardial blood ﬂow in
addition to relative regional perfusion analysis. To evaluate
myocardial blood ﬂow, the ﬁrst-pass extraction percentage
of the tracer represents an important tracer characteristic,
and for this reason, O-15 water is widely considered as the
most ideal ﬂow tracer due to its ﬁrst-pass extraction of
100%. Furthermore, F-18-labeled compound BMS747158
(
18F-BMS) is considered another high potent tracer for
myocardial ﬂow imaging as it shows a ﬁrst-pass extraction
percentage exceeding 90% [13, 14].
With the use of PET tracers, simultaneous conventional
image analysis (relative regional perfusion and function)
and absolute ﬂow quantiﬁcation can be performed, as
illustrated schematically in Fig. 1. Dynamic imaging with
multiple time frames requires a high count density and
advanced data processing, which is increasingly becoming
a routine feature in the novel state-of-the-art PET systems.
For tracer kinetic analysis, the arterial input function and
myocardial kinetics are measured from regions of interest
in sequential (dynamic) images. Absolute ﬂow quantiﬁca-
tion is achieved by employing compartmental modeling
analysis to the obtained time–activity curves. At present,
various tracer kinetic models have been established
according to the nature of the each PET tracer [15, 16], and
validation studies have been performed in experimental
settings. Although several comparison studies have noted
distinct differences between PET tracers, a good repro-
ducibility for ﬂow measurements has been established,
which underlines the feasibility of PET imaging for
assessment of myocardial blood ﬂow [17–19].
Currently, several studies using PET imaging have
demonstrated that myocardial blood ﬂow and ﬂow reserve
are inﬂuenced by a number of factors. On the one hand,
myocardial blood ﬂow and ﬂow reserve are strongly
inﬂuenced by systemic cardiovascular hemodynamics as
well as aging [20]. Aging, increasing heart rate and
increasing systemic blood pressure cause an augmented
baseline work of the heart, leading to a higher rest myo-
cardial blood ﬂow. Accordingly, the myocardial ﬂow
reserve, which is expressed as the ratio of stress to rest
ﬂow, will be reduced. Furthermore, nuclear studies have
shown that myocardial blood ﬂow and ﬂow reserve can be
inﬂuenced by conventional cardiovascular risk factors,
such as smoking, dyslipidemia, and diabetes [21, 22].
Additionally, it has been postulated that therapeutic inter-
ventions and cardiovascular risk modiﬁcation can inﬂuence
myocardial blood ﬂow or ﬂow reserve of the heart [20–22].
Table 1 Myocardial perfusion PET/SPECT tracers
Half-life Production First-pass extraction (%) Kinetic properties
SPECT tracers
201Thallium 73 h Delivery 70 Na/K ATPase channel
99mTc-tetrofosmin 6 h Generator/delivery 40 Diffusible, mitochondrial binding
99mTc-sestamibi 6 h Generator/delivery 50 Mitochondrial membrane potential
PET Tracers
13NN H 3 10 min Cyclotron 85 Metabolic trapping
82Rb 76 s Generator 65 Na/K ATPase channel
15OH 2O 122 s Cyclotron 100 Freely diffusible
18F BMS747158 110 min Cyclotron/Delivery 90 Binds to mitochondrial complex-1
PET positron emission tomography, SPECT single-photon emission computed tomography
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123Gould et al. [21] evaluated whether intensive cholesterol-
lowering treatment would decrease myocardial perfusion
abnormalities in 12 patients with known coronary athero-
sclerosis. Rest-dipyridamole PET imaging was used to
evaluate myocardial perfusion defects. The study showed
that myocardial perfusion defects were signiﬁcantly smal-
ler after a 90-day period with cholesterol-lowering treat-
ment when compared to a control period without
cholesterol-lowering treatment (P\0.05).
In patients with advanced coronary artery disease, it is
well known that coronary ﬂow reserve is reduced due to the
obstructive, ﬂow-limiting nature of macroscopic disease. In
this setting, impaired ﬂow reserve has been shown to have
prognostic value for predicting adverse outcome [23, 24].
Interestingly, in coronary artery disease, coronary ﬂow
reserve may not only be impaired in areas supplied by
stenotic vessels, but also in those supplied by non-stenotic
vessels [25], emphasizing the incremental value of coro-
nary ﬂow reserve over measurements of atherosclerosis and
relative regional perfusion. It has been shown that in the
absence of macroscopic coronary artery disease, global
ﬂow reserve can be impaired in heart failure as a conse-
quence of microvascular dysfunction. For instance, a
reduced coronary ﬂow reserve has been observed in
patients with idiopathic cardiomyopathies that was not
related to peripheral arterial function [26]. Initially, it was
thought that impaired ﬂow in the failing heart, in the
absence of coronary stenosis, was secondary to impaired
contractile function, increased wall stress and other
mechanical factors [27]. More recently, however, the
concept of microvascular dysfunction as an independent
contributor to the progression of heart failure in cardio-
myopathy has been supported by a number of outcome
studies [28, 29]. Neglia et al. [28] evaluated whether
myocardial blood ﬂow impairment was predictive for
adverse events in 67 patients with idiopathic dilated car-
diomyopathy. At baseline, patients underwent rest-stress
PET imaging protocol with
13NH3. During a mean follow-
up of 45 ± 37 months, cardiac death was documented in
8 patients and worsening of heart failure in 16 patients. The
Fig. 1 Schematic display of ﬂow quantiﬁcation, static perfusion
images, and functional assessment from list mode acquisition data by
a positron emission tomography (PET) system. List mode acquisition
can be started at the same time of tracer injection. Electrocardio-
graphic and respiratory gating signals are sampled in addition to
continuous acquisition of images (left upper panel). After acquisition,
data are re-sampled and re-framed for each image analysis (left lower
panel). For ﬂow quantiﬁcation, a small region of interest is positioned
in the left ventricle (LV) and time–activity curves for LV input and
myocardium are plotted (right upper panel). Subsequently, tracer
kinetic modeling is applied to obtain ﬂow maps under resting and
hyperemic stress conditions (right lower panel)
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123results highlighted that a reduced myocardial blood ﬂow
(less than 1.36 ml/min/g) during pharmacological stress
was a predictor of adverse cardiac events [28]. Similarly,
Cecchi et al. [29] showed that impaired global stress ﬂow
and ﬂow reserve as derived from PET imaging were
independent predictors of cardiac death, worsening heart
failure or sustained ventricular arrhythmias in 51 patients
with hypertrophic cardiomyopathy.
Sympathetic innervation in the failing heart
In addition to myocardial blood ﬂow, the neurohormonal
system consisting of the sympathetic nervous system and
the renin–angiotensin–aldosterone axis plays an important
role in patients with heart failure [4–7].
Inpatients with areducedcardiacoutput,thesympathetic
nervous system becomes activated by high-pressure baro-
receptors located in the myocardium of the left ventricle
(LV), aortic arch and carotid sinus. Subsequently, afferent
neuronal signals are transferred from the baroreceptors to
cardio-regulatory centers of the central autonomic nervous
system, after which the cardiac sympathetic nervous system
istriggered.Severaleffects onthecardiovascularsystem are
caused by the activated sympathetic nervous system,
including increased peripheral vasoconstriction and heart
rate as well as an improved cardiac contractility [4–7].
Furthermore, a decline in effective renal arterial perfusion
leads to activation of the renin–angiotensin–aldosterone
axis which plays an evident role in the maintenance of
cardiac output by providing positive inotropic and chrono-
tropic support to the dysfunctional heart. Moreover, it aims
to preserve systemic arterial blood pressure by sodium and
water retention as well as acting directly on arterial smooth
muscle cells as a vasoconstrictor.
The function of the sympathetic nervous system is pri-
marily mediated by the production, uptake and release of
norepinephrine (neurotransmitter) from the presynaptic
cleft. After tyrosine is converted to norepinephrine, two
important mechanisms control predominantly the amount
of norepinephrine within the presynaptic cleft: the uptake-1
(neuronal) and uptake-2 (non-neuronal) mechanisms.
Norepinephrine can be cleared from the synaptic cleft by
either the norepinephrine transporter (NET) protein
(uptake-1) located at the dilated endings of the sympathetic
neuron or the sodium-dependent non-neuronal transport
mechanism (uptake-2) located at the post-synaptic site of
the cleft. Importantly, in patients with heart failure, these
uptake mechanisms of norepinephrine can be used to
visualize myocardial sympathetic innervation and activa-
tion patterns [9, 30].
Myocardial sympathetic innervation and activation can
be assessed non-invasively using dedicated imaging
protocols with SPECT or PET tracers [9, 30]. Both SPECT
and PET imaging allow non-invasive visualization of
regional and global abnormalities in cardiac sympathetic
innervation and activation.
Neuronal imaging with SPECT
Scintigraphic assessment of cardiac sympathetic innerva-
tion and activation can be performed with the use of
SPECT tracers [8, 30]. Currently, cardiac sympathetic
neuronal imaging has been performed most commonly
with radionuclide imaging of the norepinephrine analog
metaiodobenzylguanidine (MIBG) labeled with 123-iodine
(123-I) [31–33]. Over the last decades, it has been shown
that 123-I MIBG represents a safe and reliable SPECT
tracer that can be used to depict the sympathetic nerve
system in patients with heart failure [31–35]. MIBG rep-
resents a false neurotransmitter that can be cleared from the
sympathetic cleft by either the uptake-1 (neuronal) or
uptake-2 (non-neuronal) mechanisms. Of note, a small
amount of MIBG can also be transferred into sympathetic
neurons or cardiomyocytes by means of passive diffusion
[8, 30]. 123-I MIBG is suitable for non-invasive mapping
of the sympathetic nervous system as it shows resistance to
metabolic degradation by monoamine oxidase or catechol-
o-methyl transferase within the sympathetic neuron, lead-
ing to enhanced accumulation of 123-I MIBG within
storage vesicles of the neurons. At present, 123-I MIBG
images are usually acquired with a two-step protocol at
10–20 min (early imaging) and 3–4 h (delayed imaging)
after tracer administration [36]. Planar and SPECT imaging
are performed in the early and late phase of the 123-I
MIBG imaging protocol. Planar images are usually
acquired from the left-anterior oblique view and provide
information on global sympathetic innervation pattern
(Fig. 2a), whereas tomographic images (SPECT imaging)
are used to assess regional abnormalities in cardiac sym-
pathetic innervation (Fig. 2b).
Most commonly, the heart-to-mediastinum (H/M) ratio
is determined on planar imaging by dividing the mean
counts per pixel within the cardiac region of interest by the
mean counts per pixel within the upper mediastinum.
Additionally, time-dependent kinetics can be evaluated by
means of the myocardial washout; the rate in which 123-I
MIBG is washed out of the myocardium. Myocardial 123-I
MIBG washout rate reﬂects the degree of sympathetic
activation of the heart [36].
Heart failure patients with severe deprived cardiac
sympathetic innervation tend to have worse prognosis
when compared to heart failure patients with relatively
preserved neuronal integrity [31–33]. Anastasiou-Nana
et al. [37] evaluated whether sympathetic nerve imaging
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123with 123-I MIBG was predictive for adverse events in 52
patients with heart failure. MIBG uptake on planar imaging
(HR 0.017, 95% CI 0.00–0.79, P = 0.038) was a predictor
for all-cause mortality, in addition to peak oxygen con-
sumption (HR 0.83, 95% CI 0.70–0.98, P = 0.031) and
pulmonary capillary wedge pressure (HR 1.06, 95% CI
1.00–1.12, P = 0.038). Furthermore, studies have also
shown that the rate in which 123-I MIBG is washout out of
the myocardium is important for prognostication of
patients with heart failure [38–40].
Recently, the AdreView Myocardial Imaging for Risk
Evaluation in Heart Failure (ADMIRE-HF) trial evaluated
the prognostic value of cardiac 123-I MIBG imaging in 961
patients with heart failure [33]. All subjects underwent
cardiac 123-I MIBG planar and SPECT imaging as well as
myocardial perfusion imaging with
99mTc-tetrofosmin.
Patients were monitored until they reached the pre-deter-
mined follow-up period of 2 years or until adverse major
cardiac events were documented; progression of heart
failure, potentially lethal arrhythmias or cardiac death.
Patients with adverse events showed signiﬁcantly lower
early and late H/M ratio (P\0.01) as well as higher
myocardial washout rate (P\0.01) than patients without
adverse events during follow-up. Most important, the risk
for major cardiac events was signiﬁcantly lower in patients
with H/M ratio C 1.60 when compared to patients with
H/M ratio\1.60 (HR 0.40, 95% CI 0.25–0.64, P\0.01)
(Fig. 3). Accordingly, this study conﬁrmed the previously
reported predictive value of cardiac 123-I MIBG imaging
in patients with heart failure.
Sympathetic denervation of the myocardium is also
thought to play an evident role in the development of life-
threatening ventricular arrhythmias and sudden arrhythmic
death [41, 42]. Viable myocardium with deprived sympa-
thetic innervation may serve as a substrate for ventricular
arrhythmias as these regions show an increased automa-
ticity and triggering to external sympathetic stimuli, when
Fig. 2 Cardiac sympathetic nerve imaging with 123-iodine metaiod-
obenzylguanidine (123-I MIBG) can be used to assess global (panel
A) and regional (panel B) sympathetic innervation in patients with
heart failure. a Global reduction of 123-I MIBG uptake (sympathetic
denervation) in a patient with advanced heart failure. The heart-to-
mediastinum (H/M) ratio on late planar imaging was calculated by
dividing the mean counts per pixel within the heart (H) by the mean
counts per pixel within the upper mediastinum (M). In this example,
the late H/M ratio was 1.31. b An example of regional abnormalities
in sympathetic innervation is illustrated below (as indicated by
regional defect in 123-I MIBG uptake, white arrow)
Fig. 3 Cumulative event rates for heart failure patients with heart-to-
mediastinum (H/M) ratio\1.60 and patients with H/M ratio C 1.60
on late planar 123-iodine metaiodobenzylguanidine (123-I MIBG)
imaging. The composite primary endpoint of heart failure progres-
sion, potential lethal arrhythmic events or cardiac death was
signiﬁcantly more documented in patients with late H/M ratio\1.60
when compared to patients with late H/M ratio C 1.60 at 2-year of
follow-up (38 vs. 15%, P\0.01). Reprinted with permission from
reference 33
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123compared to viable regions with preserved neuronal
integrity [41, 42]. To date, several studies have explored
the role of cardiac 123-I MIBG imaging for prediction of
ventricular arrhythmias, sudden cardiac death, or appro-
priate implantable cardioverter-deﬁbrillator (ICD) dis-
charge [33, 43–47]. In 961 patients with heart failure,
Jacobson et al. [33] demonstrated that patients with
preserved myocardial sympathetic innervation (H/M
ratio C 1.60) had signiﬁcantly less arrhythmic events when
compared to patients depressed sympathetic innervation
(H/M ratio\1.60) (HR 0.37, 95% CI 0.16–0.85,
P = 0.02) during a median follow-up of 17 months. In
addition, regional abnormalities in sympathetic innervation
are also likely to play a role in the development of ven-
tricular tachyarrhythmias [43, 47]. The role of cardiac
sympathetic nerve imaging with 123-I MIBG was also
evaluated in 116 patients with advanced heart failure who
were clinically referred for ICD implantation [47]. Patients
with ventricular arrhythmias causing appropriate ICD dis-
charge (primary endpoint) showed signiﬁcantly more
regional sympathetic denervation (as expressed in summed
123-I MIBG SPECT defect score) when compared to
patients without appropriate ICD discharge (P\0.05)
(Fig. 4). Moreover, late 123-I MIBG SPECT defect score
was independently associated with the occurrence of
appropriate ICD discharges (HR 1.13, 95% CI 1.05–1.21,
P\0.01).
Beyond regional sympathetic denervation, it has been
suggested that hyperactivity of the cardiac sympathetic
nervous system (increased sympathetic tone) is associated
with the occurrence of potential lethal ventricular arrhyth-
mias and sudden cardiac death [45, 48]. Moreover, it has
been demonstrated that enhanced activation of beta-adren-
ergic receptors within the myocardium, which results from
a chronic up-regulated sympathetic tone, could initiate
ventricular tachycardia via non-reentrant mechanisms in
heart failure patients [49]. An important study was per-
formed by Tamaki and colleagues [45] who sought to
determine the value of cardiac 123-I MIBG imaging for
prediction of sudden arrhythmic death in 106 outpatients
with chronic heart failure and LV ejection fraction
(LVEF)\40%. Patients with sudden cardiac death showed
signiﬁcantly lower early (1.72 ± 0.29 vs. 1.87 ± 0.26, P =
0.036) and late (1.54 ± 0.25 vs. 1.76 ± 0.31, P\0.01)
H/M ratio as well as signiﬁcantly higher myocardial
washout rate (39.9 ± 15.2% vs. 27.6 ± 14.2%, P\0.01),
than patients who survived the mean follow-up of
65 ± 31 months, as depicted in Fig. 5. Importantly,
only myocardial washout rate (HR = 1.052, 95% CI
Fig. 4 Cardiac 123-iodine
metaiodobenzylguanidine
(123-I MIBG) imaging allows
prediction of ventricular
arrhythmias causing appropriate
implantable cardioverter-
deﬁbrillator (ICD) therapy in
heart failure patients. Patients
with a large defect on late 123-I
MIBG SPECT imaging
(summed defect score[26)
showed signiﬁcantly more
ventricular arrhythmias when
compared to patients with a
small defect on late 123-I MIBG
SPECT imaging (summed
defect score B 26) at 3-year of
follow-up (52 vs. 5%,
P\0.01). Reprinted with
permission from reference 47
Fig. 5 Cardiac 123-iodine metaiodobenzylguanidine (123-I MIBG)
planar imaging in patients with (n = 18) and without (n = 88)
sudden cardiac death. Myocardial washout rate was signiﬁcantly
higher in patients with sudden cardiac death when compared to
patients without sudden cardiac death (39.9 ± 15.2% vs.
27.6 ± 14.2%, P = 0.0013) during a mean follow-up period of
65 ± 31 months. Data were based on reference 45
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1231.020–1.085, P\0.01) and LVEF (HR = 0.930, 95% CI
0.870–0.995, P = 0.0341) were independent predictors for
sudden arrhythmic death.
One issue that needs to be addressed is the existing
heterogeneity of data acquisition and image analyses
among the available 123-I MIBG studies. Standardization
of data acquisition and post-processing techniques may
further contribute to clinical implementation of cardiac
123-I MIBG imaging for prognostication of heart failure
patients [36].
Neuronal imaging with PET
PETrepresentsahighlydedicatedscintigraphictechniqueto
map the cardiac sympathetic nervous system, with superior
spatial and temporal resolution when compared to SPECT
imaging [9]. With the currently applied PET scanners and
post-processing algorithms, images can be reconstructed
with aspatialresolution of4–7 mm. Moreover,its relatively
hightemporalresolutionallowsthedevelopmentofdynamic
images which can be used to assess tracer kinetics. Impor-
tantly, with the use of validated photon attenuation and
scatter correction algorithms, PET imaging can be used to
quantify the absolute amount of nuclear tracer within the
myocardium and its time-dependent kinetics [9].
At present, a wide variety of PET tracers allow assess-
ment of sympathetic innervation and activation of the
heart. Basically, available PET tracers are divided into (1)
radiolabeled catecholamines and (2) radiolabeled cate-
cholamine analogs. Radiolabeled catecholamines are
molecular identical to endogenous neurotransmitters, and
therefore, they will undergo similar uptake, release and
metabolic pathways within the myocardium and sympa-
thetic neurons, whereas the radiolabeled catecholamine
analogs (also referred to as false neurotransmitters) follow
the same uptake and release mechanisms, without being
metabolized like the endogenous transmitters. Hydroxy-
ephedrine labeled with carbon-11 (
11C-HED) represents
one of the most frequently applied PET tracer for cardiac
sympathetic nerve imaging as it shows high afﬁnity for the
uptake-1 transporter located on the presynaptic nerve ter-
minal. In addition,
11C-HED can be used for accurate
assessment of regional neuronal defects as it has been
shown to distribute equally within the myocardium in
physiologic conditions. Thus far, several studies have
aimed to describe sympathetic neuronal defects in heart
failure patients using PET imaging with
11C-HED [50–56].
Hartmann et al. [51] have assessed cardiac sympathetic
innervation patterns in 29 patients with severely dilated
cardiomyopathy and heart failure as well as in 8 healthy
volunteers. Gated blood-pool imaging was performed to
obtain LV systolic function. In all patients, the PET
imaging protocol consisted of a resting perfusion scan with
13NH3 combined with a dynamic PET scan using
11C-HED.
The study demonstrated that global retention of
11C-HED
was signiﬁcantly lower in patients diagnosed with heart
failure when compared to the healthy control patients (6.2
(1.6) %/min vs. 10.7 (1.0) %/min, P\0.01). Moreover,
PET imaging was also able to detect signiﬁcant regional
neuronal defects in apical (P\0.01) and inferoapical
(P\0.05) myocardial segments of patients with heart
failure. In these segments, the
11C-HED/perfusion ratio
showed a progressive and signiﬁcant (P\0.05) decline
when compared to the basal cardiac segments.
Cardiac innervation has also been explored in heart
failure patients who underwent cardiac transplantation; in
particular, re-innervation was demonstrated after trans-
plantation. Bengel et al. [54] evaluated cardiac sympathetic
innervation in 27 asymptomatic patients with previous
orthotopic heart transplantation. With
11C-HED PET
imaging, cardiac sympathetic re-innervation was observed
in 14 of the 27 patients. Di Carli et al. [57] performed
another study that evaluated cardiac sympathetic innerva-
tion in patients with previous cardiac transplants. In total,
14 patients underwent PET imaging with
11C-HED. The
results indicated that sympathetic uptake of
11C-HED was
signiﬁcantly higher in the territory served by the left-
anterior descending artery when compared to those served
by the right coronary artery or circumﬂex artery.
In addition, neuronal imaging with PET has also been
used to evaluate the relation between cardiac sympathetic
innervation and ventricular arrhythmias [58]. In 11 pigs,
myocardial infarction was induced by balloon occlusion of
the left-anterior descending coronary artery. Subsequently,
PET imaging was performed to evaluate myocardial per-
fusion and sympathetic innervation of the myocardium.
Invasive electrophysiological testing was performed to
evaluate the inducibility of ventricular arrhythmias. Ani-
mals with inducible ventricular tachycardia showed a
larger perfusion/innervation mismatch when compared to
animals without inducible ventricular tachycardia (10 ±
4% vs. 4 ± 2%, P = 0.02). Furthermore, the extent of
perfusion/innervation mismatch was signiﬁcantly corre-
lated to reduced myocardial voltage (r = 0.93, P = 0.001)
and the site of earliest ventricular tachycardia (chi-square
13.1, P\0.001).
Future role of nuclear imaging in heart failure
While myocardial blood ﬂow and neuronal imaging are
increasingly used in clinical cardiology, a variety of
molecular-targeted tracers is being evaluated on the pre-
clinical level. These preclinical tracers have in common
that they target key mechanisms involved in (1) early
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123development of heart failure and (2) novel therapeutic
interventions for heart failure. It is expected that ongoing
efforts that aim to establish these advanced molecular
imaging techniques will lead to the transition from pre-
clinical to clinical use in the near future.
Nuclear imaging for prevention of overt heart failure
Insight into the underlying mechanisms involved in the
transition from regional ischemia and infarction toward
global heart failure, i.e., LV remodeling, may substantially
improve the prevention of overt organ failure. In this per-
spective, targeted visualization of biomechanisms involved
in cardiac remodeling may help to identify individuals at
risk for progression of ventricular dysfunction in an early
phase. It has been recognized that matrix metalloprotein-
ases (MMPs), which are proteolytic enzymes, play an
important role in remodeling of the heart [59]. For exam-
ple, Mukherjee et al. [60] demonstrated a reduction of post-
myocardial LV dilatation and expansion of myocardial
infarction by MMP inhibition in pigs. Furthermore, imag-
ing of MMP upregulation after myocardial infarction was
reported by Su et al. [61]. This study demonstrated a
ﬁvefold increased uptake of an MMP-targeted tracer
(In-111RP782)withintheinfarctareaandatwofoldincrease
in remote areas in a rodent model of myocardial infarction.
In addition, cardiac remodeling has also been linked to
other biomechanisms, including myocardial substrate uti-
lization [62], sympathetic nervous system [63], renin–
aldosterone–angiotensin system [64], adhesion molecules
such as alphavbeta3 integrin [65, 66], and growth factors
such as VEGF [67]. All of these mechanisms seem to be
activated early after myocardial infarction, and they are
thought to contribute to ongoing deterioration of ventric-
ular function. The hope is that non-invasive visualization of
patterns of activation early after infarction will allow to
predict individual risk for remodeling, and to guide speciﬁc
therapy directed against these processes [68]. Accordingly,
these dedicated imaging techniques may allow more
effective prevention of heart failure in the future.
Nuclear imaging for monitoring molecular
interventions
Advances in the understanding of heart failure etiology and
pathophysiology have led to the introduction of novel
molecular interventions for patients with heart failure, such
as gene and cell therapy. These novel interventions have
entered the therapeutic arena to provide treatment solutions
based on speciﬁc disease mechanisms. However, despite
the fact that these novel therapies are promising, some
basic principles are currently still not well-understood.
For instance, several important methodological issues
regarding appropriate therapeutic strategy (e.g., timing,
dose and route) as well as the type of study endpoints need
to be addressed in additional studies.
In patients with heart failure, efﬁcient cell engraftment
and subsequent cell survival are of high importance for the
success rate of cell transplantation therapies. At present,
several techniques for visualization and monitoring of
transplanted cells in the heart have been proposed. The
most straightforward approach is direct labeling of cells
prior to their application with an agent that can be detected
by an in vivo imaging system. Currently, therapeutic cells
have already been labeled with paramagnetic substances
such as iron oxides for magnetic resonance imaging [69],
and with radionuclides such as In-111 oxin [70] and 18F-
ﬂuorodeoxyglucose (
18F-FDG) [71] for nuclear imaging.
An example image of preclinical studies using
18F-FDG-
labeled cardiac derived stem cells in rat infarction model is
shown in Fig. 6. This technique allows the visualization of
location and survival of delivered cells and myocardial
perfusion in the same imaging session. Despite its high
sensitivity, the half-life of radiotracers (
111In is 67 h, and
Fig. 6 Fused positron emission tomography (PET) images of 18F-
ﬂuorodeoxyglucose (
18F-FDG)-labeled stem cells (solid arrows) and
N-13 Ammonia (
13NH3) myocardial perfusion in rat infarction model.
Radiolabeled stem cells were administrated intramyocardially into the
infracted region. Subsequently, FDG images conﬁrmed the orienta-
tion and survival of delivered cells (solid arrow) with the reference of
ammonia perfusion image which showed a large defect in the anterior
region (dotted arrows)
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ered cells.
Another approach for monitoring transplanted cells is
reporter gene imaging, which has been introduced initially
for speciﬁc monitoring of the transfer and expression of
exogenous genes in the myocardium [72]. The donor cells
are genetically modiﬁed to express reporter gene prior to in
vivo transplantation. Imaging requires stable transduction
of genes after cell transplantation, thereby encoding
gene products that mediate accumulation of a radioactive
reporter probe within the donor cell. The reporter gene will
be continuously expressed as long as cells are viable, but
will be silent after cell death. Therefore, imaging of the
reporter mediated tracer accumulation provides a speciﬁc
signal for longer-term graft cell survival [73]. Thus far,
several experimental studies have proofed the principle of
reporter gene imaging of transplanted cells [73, 74].
These techniques for cell tracking can be used to obtain
valuable insights into determinants of cell engraftment; the
presence of a low number of engrafted cells could explain
the limited success of the particular procedure. Using direct
cell labeling and quantiﬁcation, it has recently been shown
that a large fraction of cells is already lost very early after
injection into the myocardium [75]. Subsequently, several
techniques to mechanically retain the cells in the myocar-
dium (such as e.g., sealing of the injection site with ﬁbrin
glue) have been suggested, and those may be beneﬁcial for
the success of cell therapy in the future.
The success of each of these novel molecular imaging
methodologies will depend on the clinical success of each
of the respective molecular therapeutic intervention. It is
likely, however, that efforts in molecular imaging and
therapy in general will both contribute to the advances in
heart failure treatment and prevention.
Summary
Heart failure represents an important pathophysiologic
condition with markedly increased morbidity and mortality
rates over the last decades. Myocardial blood ﬂow and
perfusion have been identiﬁed as important parameters in
patients with heart failure. Nuclear imaging with SPECT is
routinely used, but PET allows absolute for the quantiﬁ-
cation of myocardial blood ﬂow beyond the assessment of
relative myocardial perfusion, which may be beneﬁcial, in
speciﬁc patients. Both PET and SPECT can be used for
diagnosis, treatment options, and prognosis in patients with
heart failure.
Cardiac sympathetic innervation is also important in
patients with heart failure. SPECT imaging with 123-I
MIBG permits visualization of cardiac sympathetic
innervation of the failing heart. Abnormal sympathetic
innervation and activation, as assessed with 123-I MIBG is
predictive of cardiac mortality, morbidity, and ventricular
arrhythmias or sudden cardiac death in patients with heart
failure. Accordingly, cardiac 123-I MIBG imaging will be
important for prognosis in patients with heart failure.
Recent emphasis is put on the development of novel
nuclear imaging techniques that will target speciﬁc bio-
logic processes of the failing heart. These molecular-tar-
geted imaging techniques will provide further insight into
the pathophysiology of the failing heart and may poten-
tially be used for early detection of heart failure as well as
monitoring new therapeutic interventions.
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